Brianna Abbott Health Reporter Wall Street Journal Brianna Abbott is a health reporter covering the treatment and prevention of disease, with a special focus on cancer, in The Wall Street Journal’s Health and Science bureau. She writes stories about cutting-edge scientific research, patient care, and public health. She also covers health and screening recommendations and the agencies that produce them.In 2023, she and her colleagues won a New York Press Club Award in the Feature-Science Medicine & Technology category for their Covid-19 coverage. Previously, she attended the Science, Health and Environmental Reporting Program at New York University and studied chemistry and creative writing at Providence College in Rhode Island. Brianna joined the Journal in 2019 following an internship with the newspaper.Source: The Wall Street Journal More from Brianna Prostate Cancer News When Screening for Prostate Cancer Comes Too Late Prostate cancer screening methods are under review for better targeting high-risk groups and addressing stagnant death rates and late-stage diagnoses.
Brianna Abbott is a health reporter covering the treatment and prevention of disease, with a special focus on cancer, in The Wall Street Journal’s Health and Science bureau. She writes stories about cutting-edge scientific research, patient care, and public health. She also covers health and screening recommendations and the agencies that produce them.In 2023, she and her colleagues won a New York Press Club Award in the Feature-Science Medicine & Technology category for their Covid-19 coverage. Previously, she attended the Science, Health and Environmental Reporting Program at New York University and studied chemistry and creative writing at Providence College in Rhode Island. Brianna joined the Journal in 2019 following an internship with the newspaper.Source: The Wall Street Journal
More from Brianna Prostate Cancer News When Screening for Prostate Cancer Comes Too Late Prostate cancer screening methods are under review for better targeting high-risk groups and addressing stagnant death rates and late-stage diagnoses.
